reports
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-R...
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy ERAS-0015’s promising early clinical data underscore its potential to be a best-in-class RAS-targeting agent Initial Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing the...
- Jonathan Moreland
TPC TUTOR PERINI CORPORATION
NMFC NEW MOUNTAIN FINANCE CORPORATION
LTC LTC PROPERTIES INC.
FFIN FIRST FINANCIAL BANKSHARES INC
WD WALKER & DUNLOP INC.
SSP THE E.W. SCRIPPS COMPANY
DCTH DELCATH SYSTEMS
U UNITY SOFTWARE INC.
HR HEALTHCARE TRUST OF AMERICA INC.
EFSI EAGLE FINANCIAL SERVICES INC
CGON CG ONCOLOGY INC
NCDL NUVEEN CHURCHILL DIRECT LENDING CORP
EDSA EDESA BIOTECH INC
PMN PROMIS NEUROSCIENCES INC.
HYMC HYCROFT MINING HOLDING CORPORATION
CORRECTION - Blink Charging Teams with Korian to Offer Expanded EV Inf...
CORRECTION - Blink Charging Teams with Korian to Offer Expanded EV Infrastructure Throughout Belgium Three Sites Now Live as Blink Advances EV Charging Rollout of 220 Planned Charging Ports Across 90 Korian Locations Throughout Belgium Antwerp, BELGIUM, March 05, 2026 (GLOBE NEWSWIRE) -- Belgium, a provider of elderly care services, has selected (NASDAQ: BLNK) (“Blink” or the “Company”), a leading global owner, operator and provider of electric vehicle (EV) charging equipment and services, as its EV charging collaborator for a nationwide EV charging project. For this collaboration, Bli...
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Eva...
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collabora...
- Jonathan Moreland
RUN SUNRUN INC.
PYPL PAYPAL HOLDINGS INC
NMFC NEW MOUNTAIN FINANCE CORPORATION
GPK GRAPHIC PACKAGING HOLDING COMPANY
FMNB FARMERS NATIONAL BANC CORP.
DIN DINE BRANDS GLOBAL INC.
ACIW ACI WORLDWIDE INC.
WD WALKER & DUNLOP INC.
TTEC TELETECH HOLDINGS
AXR INC.
PCB AMREP
TSLX PACIFIC CITY FINANCIAL CORP
FOUR SIXTH STREET SPECIALTY LENDING
THRY INC.
EOSE SHIFT4 PAYMENTS
LUNG INC.
AIRS THRYV HOLDINGS
TTD EOS ENERGY ENTERPRISES INC (A)
FBRT PULMONX
BLCO AIRSCULPT TECHNOLOGIES INC
GTE THE TRADE DESK
EDSA FRANKLIN BSP REALTY TRUST INC
LAW BAUSCH + LOMB CORP
PMN GRAN TIERRA ENERGY INC.
EDESA BIOTECH INC
CS DISCO INC
PROMIS NEUROSCIENCES INC.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nas...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on March 2, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 2,931 shares of its common stock to fourteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (th...
Blink Charging Teams with Korian to Offer Expanded EV Infrastructure T...
Blink Charging Teams with Korian to Offer Expanded EV Infrastructure Throughout Belgium Three Sites Now Live as Blink Advances EV Charging Rollout of 220 Planned Charging Ports Across 90 Korian Locations Throughout Belgium Antwerp, BELGIUM, March 04, 2026 (GLOBE NEWSWIRE) -- Belgium, a provider of elderly care services, has selected (NASDAQ: BLNK) (“Blink” or the “Company”), a leading global owner, operator and provider of electric vehicle (EV) charging equipment and services, as its EV charging collaborator for a nationwide EV charging project. For this collaboration, Blink plans to i...
Insight Molecular Diagnostics Completes Key Milestones Advancing Graft...
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission Three-site reproducibility study completed by Tampa General Hospital, Mayo Clinic, and Baylor Scott & White HealthSufficient clinical samples collected to support statistical analysis and FDA submissionCompany achieved final ISO 13485 certification on Feb. 26, enabling U.K. and E.U. regulatory submissions NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx”) today announced that in February the company completed several major miles...
Greenwich LifeSciences Provides Update on Increased Patient Screen Rat...
Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01 STAFFORD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on the increased patient screen rate in FLAMINGO-01. FLAMINGO-01 Annual Patient Screen Rate Increases to Over 800 Patients per Year Over the past 6 months, the Comp...
- Jonathan Moreland
TBK TRIUMPH BANCORP INC.
MELI MERCADOLIBRE INC.
HTGC HERCULES CAPITAL INC.
AXTI AXT INC.
LFVN LIFEVANTAGE
HRI HERC HOLDINGS INC.
SXC SUNCOKE ENERGY INC.
CSWC CAPITAL SOUTHWEST CORP.
WINA WINMARK CORP.
AWI ARMSTRONG WORLD INDUSTRIES
PCB INC.
IDYA PACIFIC CITY FINANCIAL CORP
FOUR IDEAYA BIOSCIENCES
LRMR SHIFT4 PAYMENTS
PCVX INC.
ABCL LARIMAR THERAPEUTICS INC
ACVA VAXCYTE
TBBK ABCELLERA BIOLOGICS
FSCO ACV AUCTIONS INC.
ZURA THE BANCORP
NPWR INC.
EDSA FS CREDIT OPPORTUNITIES CORP.
LAW ZURA BIO LTD
NET POWER INC
EDESA BIOTECH INC
CS DISCO INC
- Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TRIP TRIPADVISOR INC.
SRPT SAREPTA THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
SE SEA ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
BKNG BOOKING HOLDINGS INC.
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
CHWY CHEWY INC. CLASS A
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
KROS ADICET BIO INC
ZNTL KEROS THERAPEUTICS
BEAM ZENTALIS PHARMACEUTICALS
LRMR BEAM THERAPEUTICS
OCUP LARIMAR THERAPEUTICS INC
PRAX OCUPHIRE PHARMA INC
COGT PRAXIS PRECISION MEDICINES
U COGENT BIOSCIENCES INC
TVTX UNITY SOFTWARE
DASH TRAVERE THERAPEUTICS INC
ABNB DOORDASH
VRDN AIRBNB INC. CLASS A
PLTK VIRIDIAN THERAPEUTICS INC
NUVB PLAYTIKA HOLDING
RBLX NUVATION BIO INC (A)
DAWN ROBLOX
TNGX DAY ONE BIOPHARMACEUTICALS INC
STX TANGO THERAPEUTICS
HOWL INC
APP SEAGATE TECHNOLOGY HLDGS PLC
TTD WEREWOLF THERAPEUTICS INC
QUBT APPLOVIN CORP
GFS THE TRADE DESK
GMTX INC.
TYRA QUANTUM COMPUTING INC
EWTX GLOBALFOUNDRIES INC
SLDB GEMINI THERAPEUTICS INC
DDI TYRA BIOSCIENCES INC
APGE EDGEWISE THERAPEUTICS INC
EMBRAC B SOLID BIOSCIENCES INC
DNTH DOUBLEDOWN INTERACTIVE CO LTD
CART APOGEE THERAPEUTICS INC
NATL EMBRACER GROUP AB
CGON DIANTHUS THERAPEUTICS INC
ORKA MAPLEBEAR INC.
BCAX NCR ATLEOS CORPORATION
ZBIO CG ONCOLOGY INC
TLX ORUKA THERAPEUTICS INC
MAZE BICARA THERAPEUTICS INC.
JBIO ZENAS BIOPHARMA INC.
TELIX PHARMACEUTICALS LIMITED
MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Robert Driscoll
- Thomas Yip
- Yun Zhong
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
STOK STOKE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
GMTX GEMINI THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
SLDB SOLID BIOSCIENCES INC
APGE APOGEE THERAPEUTICS INC
DNTH DIANTHUS THERAPEUTICS INC
ORKA ORUKA THERAPEUTICS INC
BCAX BICARA THERAPEUTICS INC.
ZBIO ZENAS BIOPHARMA INC.
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
JBIO JADE BIOSCIENCES INC
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Fina...
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance Over 1.1 million total VOQUEZNA® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from FY 2024 Q4 operating expenses of $55.9 million; non-GAAP operating expenses of $50.3 million and net cash usage of approximately $5.2 million, reflecting continued expense discipline Strengthened financial position through $130 million equity offering and modification of term debt Providing FY 2026 guidanc...
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor...
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca’s diversified IP portfolio for RAS-driven cancers Initial Phase 1 monotherapy data expected for ERAS-0015 in 1H and for ERAS-4001 in 2H 2026 SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven...
Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR A...
Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026 STAFFORD, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that two abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026, including two corresponding poster...
Phathom Pharmaceuticals to Participate in Upcoming Investor Conference...
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences FLORHAM PARK, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference in Boston, MADate: Monday, March 2, 2026Company Presentation: 10:30 am ESTManagement to participate in one-on-one mee...
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
EBAY EBAY INC.
AXTI AXT INC.
ARDX ARDELYX INC
NFLX NETFLIX INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
NICE NICE LTD
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
PLTK PLAYTIKA HOLDING
BUR BURFORD CAPITAL
RBLX ROBLOX
STX SEAGATE TECHNOLOGY HLDGS PLC
GFS GLOBALFOUNDRIES INC
SYRE SPYRE THERAPEUTICS INC.
BCAX BICARA THERAPEUTICS INC.
TLX TELIX PHARMACEUTICALS LIMITED
- Laura Chico
- Thomas Yip
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Dollar General Corporation and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 12 February 2026 in which we reassessed the appropriateness of the ratings in th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.